News & Events

BEAM Alliance
Members
Events

Latest news from BEAM Alliance

18 September 2026 - BEAM ALLIANCE

Patients need more than one antimicrobial option

Read the full paper to explore why patient benefit, rather than a winner-takes-all approach, should remain at the heart of…

30 June 2026 - BEAM ALLIANCE

Broad multidisciplinary coalition warns AMR threatens global health security and urges G7 leaders to make it a public health priority

A new international coalition of more than 60 experts and organisations is calling on G7 leaders to urgently take action…

16 June 2026 - BEAM ALLIANCE

The G7 presidency presents a unique opportunity for France to make antimicrobial resistance a strategic public health priority

As the G7 meets in Evian (Haute-Savoie) from June 15 to 17, some fifty experts call on France, in an…

21 April 2026 - BEAM ALLIANCE

Integrating Biodefence into the European Competitiveness Fund: A Strategic Imperative

This new paper highlights the urgent need to recognise antimicrobial resistance (AMR) as both a public health threat and a security…

3 March 2026 - BEAM ALLIANCE

BEAM is turning 10!

What a journey since the association was founded in 2016! Since then, awareness of the looming AMR problem has grown,…

11 December 2025 - BEAM ALLIANCE

EU Reaches Landmark Agreement on Pharmaceutical Legislation Revision

After a long night of negotiations, EU co-legislators have reached a long-awaited political agreement on the revision of the Union’s…

No results

1 / 11

Latest news of BEAM Members

20 October 2026 - Basilea Pharmaceutica International

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety,…

20 October 2026 - BioVersys

BioVersys announces publication of BV100 lung penetration and drug interaction data in two leading peer-reviewed antimicrobial journals

These two papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. BV100 has…

17 September 2026 - SNIPR Biome

SNIPR enrolls first patient in Phase 2 portion of SNIPR001 trial, expanding study to 66 patients

SNIPR001 is a CRISPR-armed phage therapeutic designed to selectively target E. coli in the gut, with the aim of preventing…

14 September 2026 - Basilea Pharmaceutica International

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Invasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders.

7 September 2026 - VAXDYN

Vaxdyn raises €11M Series A to test AMR vaccine

This funding round marks a critical step in Vaxdyn’s evolution into a clinical-stage company, allowing us to clinically validate a…

2 September 2026 - BioVersys

BioVersys granted Fast-Track Designation from US FDA for BV100

This designation underscores the significant unmet medical need for new treatment options for patients suffering from serious infections caused by…

No results

1 / 75

Events

23 March 2027

11th AMR Conference

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

9 November 2026

BIO-Europe® 2026

The must‑attend global life science partnering event where the biopharma C‑suite, investors and partners meet to set the industry agenda…

27 October 2026

REVIVE Webinar: From approval to access: A new model for delivering effective antibiotics

This webinar is about rethinking antibiotic access. Together, we’ll explore whether antibiotic use reflects resistance levels, disease burden and local…

12 October 2026

WHS 2026 side event – Tackling AMR starts with prevention: From Strategy to Implementation

BEAM Alliance together with OM Pharma will co-host at the World Health Summit 2026 a discussion around an important question…

10 October 2026

10th Interdisciplinary Course on Antibiotics & Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

29 September 2026

REVIVE Webinar: The role of investigator initiated clinical trials in advancing antimicrobial use

Leading investigators of clinical trials will present how evidence generation can support more effective, sustainable and accessible use of antibiotics.

No results

1 / 32

Legal notice | Photo credits

Connect with us

contact@beam-alliance.eu
29 Avenue Tony Garnier 69007 Lyon - France